ORIGINAL ARTICLE |
|
Year : 2014 | Volume
: 30
| Issue : 1 | Page : 33-37 |
|
External validation of the modified Glasgow prognostic score for renal cancer
Caroline G Tai1, Timothy V Johnson1, Ammara Abbasi1, Lindsey Herrell1, Wayne B Harris1, Omer Kucuk2, Daniel J Canter1, Kenneth Ogan1, John G Pattaras1, Peter T Nieh1, Viraj A Master1
1 Department of Urology, Emory University, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA 2 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
Correspondence Address:
Viraj A Master Department of Urology, 1365 Clifton Road NE, Atlanta, GA 30322, 404 217 6419 USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0970-1591.124203
|
|
Purpose: The modified Glasgow prognostic Score (mGPS) incorporates C-reactive protein and albumin as a clinically useful marker of tumor behavior. The ability of the mGPS to predict metastasis in localized renal cell carcinoma (RCC) remains unknown in an external validation cohort.
Patients and Methods: Patients with clinically localized clear cell RCC were followed for 1 year post-operatively. Metastases were identified radiologically. Patients were categorized by mGPS score as low-risk (mGPS = 0 points), intermediate-risk (mGPS = 1 point) and high-risk (mGPS = 2 points). Univariate, Kaplan-Meier and multivariate Cox regression analyses examined Recurrence -free survival (RFS) across patient and disease characteristics.
Results: Of the 129 patients in this study, 23.3% developed metastases. Of low, intermediate and high risk patients, 10.1%, 38.9% and 89.9% recurred during the study. After accounting for various patient and tumor characteristics in multivariate analysis including stage and grade, only mGPS was significantly associated with RFS. Compared with low-risk patients, intermediate- and high-risk patients experienced a 4-fold (hazard ratios [HR]: 4.035, 95% confidence interval [CI]: 1.312-12.415, P = 0.015) and 7-fold (HR: 7.012, 95% CI: 2.126-23.123 P < 0.001) risk of metastasis, respectively.
Conclusions: mGPS is a robust predictor of metastasis following potentially curative nephrectomy for localized RCC. Clinicians may consider mGPS as an adjunct to identify high-risk patients for possible enrollment into clinical trials or for patient counseling |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|